# Pizarra — PT-pseudo_2eef4115a253 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2eef4115a253
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 59-year-old male
  - PSA: 2.11 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.058 ng/mL²
  - PSA velocity: -0.04 ng/mL/yr
  - Prior PSA: 2.1 ng/mL
  - Prostate volume: 36.08 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7737494 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 2.11 ng/mL. PI-RADS 4. PSAD 0.06. Prostate volume 36 mL. csPCa 0.77.

Vitals: weight 85 kg, height 182 cm, BMI 25.7, BP 117/84 mmHg, HR 73 bpm. Smoking: Ex-smoker (36 pack-yr, quit 2021).

Chief complaint: Evaluation requested after imaging revealed a left peripheral zone abnormality alongside a recent PSA elevation.

History: At 59 years of age, the patient works as a retired shopkeeper. He is divorced and currently resides with his partner. A former smoker, he accumulated 36 pack-years before cessation in 2021. Daily activity remains largely sedentary, punctuated by brief walks. Moderate voiding complaints dominate the history, specifically nocturia and a diminished urinary stream, correlating with an IPSS score of 19. He explicitly denies haematuria or pelvic discomfort. No chronic comorbidities exist, and he takes no active medications. Alcohol intake averages two units per week. An Arabic interpreter will be required during the consultation to facilitate precise dialogue.

Physical examination: DRE — texture: symmetrically smooth; consistency: normal; asymmetry: absent; nodules: none. Vital parameters remain stable, recording a blood pressure of 117/84 mmHg alongside a regular heart rate of 73 bpm. Thoracic auscultation reveals clear lung fields, and no peripheral oedema is observed.

Patient info: retired shopkeeper; Divorced; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 2 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Pulmonary function test — known COPD follow-up; Vascular surgery — varicose veins consult.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.42 +/- 0.18   (95% CI 0.08-0.77)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.18  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.98 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant biopsy?
  - previous_notes (get_previous_notes) -> What is the prior management context and agreed-upon surveillance pathway?

This case hinges on the PI-RADS score from the MRI and the management context, as the statistical prior is inconclusive and the protocol requires specific document evidence.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel data (PSA 2.11, PI-RADS 4, PSA density 0.058, volume 36.08 mL, csPCa probability 0.77) and did not incorporate the qualitative information from the mpMRI prose, the PSA velocity (-0.04 ng/mL/yr), or the clinical context (e.g., LUTS severity, history of prior biopsies).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.42 +/- 0.18. This suggestion could be wrong because the model failed to account for the guideline criterion which mandates biopsy when PI-RADS is 3 or higher, which this patient's PI-RADS 4 score directly triggers. Furthermore, the prior did not weigh the clinical context, such as the moderate LUTS (IPSS 19), which might increase the clinical suspicion beyond what the structured panel alone suggests.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant biopsy?
previous_notes - What is the prior management context and agreed-upon surveillance pathway?
laboratory panel - What is the full laboratory panel, specifically to confirm PSA density thresholds used in guidelines?
The radiology report is critical to confirm the PI-RADS 4 finding and the previous notes are needed to understand the current surveillance pathway.

GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion. This constrains the decision by establishing a clear threshold based on the imaging finding.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_2eef4115a253", "radiology_report": "Radboudumc | 28 Jan 2025 | Prostate Multiparametric MRI\nClinical Context: Risk stratification alongside PSA 2.11 ng/mL evaluation.\nFINDINGS: The gland measures 36.08 mL overall. A roughly 12 mm focal hypointense area occupies the left peripheral zone at mid-gland level. T2-weighted sequences highlight this region. Diffusion-weighted imaging shows marked restriction, confirmed by low apparent diffusion coefficient signals. Dynamic contrast studies demonstrate early, focal enhancement compared to adjacent tissue. Pelvic lymph nodes appear unremarkable. No seminal vesicle invasion or extracapsular extension is visible.\nIMPRESSION: PI-RADS 4 lesion in the left peripheral zone mid-gland. Prostate volume 36.08 mL yielding a PSA density of 0.058 ng/mL/mL. csPCa predicted probability 0.7737494."}
get_psa_trend
{"case_id": "PT-pseudo_2eef4115a253", "psa_trend": [{"date": "Jan 2023", "val": 0.5}, {"date": "Sep 2023", "val": 1.7}, {"date": "May 2024", "val": 1.9}, {"date": "Feb 2025", "val": 2.11}]}
get_previous_notes
{"case_id": "PT-pseudo_2eef4115a253", "previous_notes": [{"date": "04 Oct 2024", "author": "Dr. E. Mulder (GP)", "text": "Discussion centered on recent laboratory data. PSA levels increased to 2.1 ng/mL, a step up from the 1.6 ng/mL recorded in September 2023. Moderate lower urinary tract complaints were noted, yielding an IPSS score of 19. Given the upward trajectory, a multiparametric MRI was scheduled for detailed assessment."}, {"date": "12 Feb 2023", "author": "Dr. E. Mulder (GP)", "text": "Routine health screening included a PSA test. The measured value stood at 1.6 ng/mL, aligning with age-appropriate norms. Voiding function remained entirely asymptomatic. Annual laboratory follow-up was arranged."}]}
NOT RETRIEVED
laboratory panel
Left closed because the moderator's agenda did not explicitly require the full laboratory panel, and the retrieved documents did not raise a specific question requiring its retrieval.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 4 lesion in the left peripheral zone mid-gland.
- psa_trend: PSA has shown a rising trend (0.5 -> 1.7 -> 1.9 -> 2.11 ng/mL).
AGAINST sampling this patient now:
- previous_notes: Patient is on an agreed surveillance pathway following an MRI, and no prior biopsy result (grade) is documented.
WHERE THIS LEANS
The PI-RADS 4 finding strongly supports biopsy according to the protocol criterion, despite the prior surveillance context.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=yes, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 2}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents, specifically the PI-RADS 4 finding from the MRI report and the rising PSA trend, strongly support the protocol criterion for biopsy. The decision is ready for the Chair to finalize.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel data (PSA 2.11, PI-RADS 4, PSA density 0.058, volume 36.08 mL, csPCa probability 0.77) and did not incorporate the qualitative information from the mpMRI prose, the PSA velocity (-0.04 ng/mL/yr), or the clinical context (e.g., LUTS severity, history of prior biopsies).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.42 +/- 0.18. This suggestion could be wrong because the model failed to account for the guideline criterion which mandates biopsy when PI-RADS is 3 or higher, which this patient's PI-RADS 4 score directly triggers. Furthermore, the prior did not weigh the clinical context, such as the moderate LUTS (IPSS 19), which might increase the clinical suspicion beyond what the structured panel alone suggests.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant biopsy?
previous_notes - What is the prior management context and agreed-upon surveillance pathway?
laboratory panel - What is the full laboratory panel, specifically to confirm PSA density thresholds used in guidelines?
The radiology report is critical to confirm the PI-RADS 4 finding and the previous notes are needed to understand the current surveillance pathway.

GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion. This constrains the decision by establishing a clear threshold based on the imaging finding.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Radboudumc | 28 Jan 2025 | Prostate Multiparametric MRI
FINDINGS: A roughly 12 mm focal hypointense area occupies the left peripheral zone at mid-gland level. Diffusion-weighted imaging shows marked restriction.
IMPRESSION: PI-RADS 4 lesion in the left peripheral zone mid-gland. Prostate volume 36.08 mL yielding a PSA density of 0.058 ng/mL/mL. csPCa predicted probability 0.7737494.

get_psa_trend
PSA trend shows a rising trajectory: 0.5 (Jan 2023) -> 1.7 (Sep 2023) -> 1.9 (May 2024) -> 2.11 (Feb 2025).

get_previous_notes
Previous notes document indicates the patient was on an agreed surveillance pathway following an MRI, and noted an upward trajectory in PSA levels leading to the current MRI scheduling.

NOT RETRIEVED
laboratory panel
Left closed because the moderator's agenda did not explicitly require the full laboratory panel, and the retrieved documents did not raise a specific question requiring its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 4 lesion in the left peripheral zone mid-gland.
- psa_trend: PSA has shown a rising trend (0.5 -> 1.7 -> 1.9 -> 2.11 ng/mL).
AGAINST sampling this patient now:
- previous_notes: Patient is on an agreed surveillance pathway following an MRI, and no prior biopsy result (grade) is documented.

WHERE THIS LEANS
The PI-RADS 4 finding strongly supports biopsy according to the protocol criterion, despite the prior surveillance context.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=yes, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 2}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fully addressed by retrieving the MRI report (PI-RADS 4), PSA trend, and previous notes. The evidence strongly leans towards biopsy based on the protocol criterion, despite the prior surveillance context. The only missing piece is the full laboratory panel, which was not required by the agenda.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The decision leans towards biopsy because the EXPERT-PROTOCOL criterion mandates it when the mpMRI shows a PI-RADS 4 lesion, which was retrieved. This finding overturned the STATISTICAL PRIOR's suggestion of no biopsy by directly triggering the guideline threshold. Although the previous notes indicated an agreed surveillance pathway, the presence of a PI-RADS 4 lesion is a new, high-risk finding that necessitates sampling.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
